1 / 4

Relapse-Free Survival and Overall Survival in TIL + IL-2 vs IL-2 Treatments: A 16.7-Year Follow-Up

This study analyzes relapse-free survival and overall survival rates between two groups: Tumor-Infiltrating Lymphocytes (TIL) + Interleukin-2 (IL-2) and IL-2 alone, over a median follow-up of 16.7 years. The difference in relapse-free survival was not significant (p=0.45). Additionally, overall survival rates did not show significant differences (p=0.39) between the two groups. Cox model analyses further evaluated the impact of factors such as Breslow thickness greater than 1.5, capsular breaking, and the presence of only one invaded lymph node on survival outcomes.

mimir
Télécharger la présentation

Relapse-Free Survival and Overall Survival in TIL + IL-2 vs IL-2 Treatments: A 16.7-Year Follow-Up

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fig. 1: Relapse-free survival in the TIL + IL-2 group: this difference was not significant (p=0.45; log-rank test); 16.7 years median follow-up.

  2. Fig. 2.: Cox model curves for the conditions Breslow >1.5, capsular breaking and only one invaded lymph node.

  3. Fig. 3. The overall survival rate between the TIL + IL-2 group and IL-2 group was not significantly different (p=0.39; log-rank test); 16.7 years median follow-up.

  4. Fig. 4. Cox survival curves in the conditions of only one nodes invaded, Breslow thickness ≥1.5 and capsular breaking

More Related